CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Sponsor
Ceric Sàrl (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04431661
Collaborator
Abbott (Industry)
131
7
40
18.7
0.5

Study Details

Study Description

Brief Summary

Out-of-hospital cardiac arrest (OHCA) is a leading cause of sudden death in Europe and the United States. Mortality is currently close to 40% among those patients who had been successfully resuscitated after OHCA associated with ventricular fibrillation or pulseless ventricular tachycardia . Coronary artery disease is observed in up to 70% of patients with OHCA and immediate coronary angiography . Current European and American guidelines recommend immediate coronary angiography with primary angioplasty in OHCA patients with ST-segment elevation on ECG after successful resuscitation . Furthermore, the identification of the culprit lesion by coronary angiography among patients with an acute coronary syndrome (ACS) and no OHCA is challenging. In a recent cardiac magnetic resonance study, Heitner et al. found that in almost half of the patients with non-ST segment elevation ACS, the culprit lesion was not properly detected or identified by coronary angiography. In the Coronary Angiography after cardiac arrest (COACT) trial, a randomized controlled trial comparing immediate versus delayed coronary angiography after OHCA in patients without ST segment elevation on ECG, some degree of coronary artery disease was found in 64.5% of the patients in the immediate angiography group and an unstable coronary lesion was identified in only 13.6% of the patients. However, in survivors of OHCA without ST segment elevation on ECG, the use of intra coronary optical computerized tomography (OCT) led to identification of plaque rupture (27%), plaque erosion (36%) and coronary thrombosis (59%) undetected on angiography. There is hence a clear need to improve causality diagnosis among patients resuscitated after OHCA and without ST segment elevation on ECG, and, in the case of coronary artery disease detection, to better identify the culprit vessel/lesion ultimately leading to a targeted treatment. These are the reasons why we have designed a prospective, multi-centre, single cohort, diagnostic accuracy study: to better explore the incidence of a true ACS among OHCA survivors and to evaluate the accuracy of angiography to detect the culprit lesion when compared to OCT.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Optical Coherence Tomography
  • Procedure: Coronary Angiography
  • Procedure: Per cutaneous coronary intervention

Study Design

Study Type:
Observational
Anticipated Enrollment :
131 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
CAOCT Study is a Prospective, Multi-centre, Single Cohort, Diagnostic Accuracy Study, Planned to Include 131 Patients in About 3 European Countries After Successful Return of Spontaneous Circulation After Out of Hospital Cardiac Arrest
Actual Study Start Date :
Jan 29, 2021
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jun 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Rate of misclassification of at least one unstable coronary artery lesion per patient, between core lab angiography and core lab OCT assessments. [Intra operative, up to 12 months]

    The core lab OCT analysis is considered as the gold standard for unstable coronary lesion detection. Detection of unstable coronary lesion by OCT includes atherosclerosis plaque rupture/erosion and thrombosis, calcified noduli with apposed thrombus, and spontaneous coronary dissection. Angiographically, unstable coronary lesions are defined as coronary lesions with at least >50% stenosis and the presence of characteristics of plaque disruption, including irregularity, dissection, haziness, or thrombus. A misclassification is either an unstable lesion detected by core lab OCT and misdiagnosed or undiagnosed on core lab angiography, or an unstable lesion as defined on core lab angiography but without plaque rupture/erosion and thrombosis, calcified noduli with apposed thrombus, and spontaneous coronary dissection on core lab OCT.

Secondary Outcome Measures

  1. The misclassification rate per coronary artery segment analysis, on angiography versus OCT (both techniques peri procedural as assessed by investigators) [Intra operative, up to 12 months]

    All analysable coronary segments according to the American Heart Association (AHA) classification (8) will be included in the final analysis. All paired (peri procedural as assessed by investigators angio and OCT) analysed segments will be included in the analysis.

  2. The percentage of patients for whom peri procedural OCT findings change their management (including revascularization strategy) when compared to the initial therapeutic strategy decided upon after investigator-assessed on-line angiography [Intra operative, up to 12 months]

    This endpoint represents a comparison between the management of the culprit lesion identified by the investigator after coronary angiography (and strictly captured in the electronic Case Report Form (eCRF) before OCT) and management of the culprit lesion as identified after OCT. Change in interventional management will include patients in whom an initially planned PCI was hold off after OCT and, vice versa, those declined a PCI in whom a PCI was finally decided after OCT. A patient for whom angiography and OCT-based diagnosis would lead to PCI of an additional but distinct coronary segment within the same vessel will be considered as a change in PCI plan.

  3. The percentage of unstable lesions (core lab OCT) intended to be left untreated by PCI after peri procedural (as assessed by investigators) angiography [Intra operative, up to 12 months]

    The percentage of unstable lesions as defined by the core lab OCT core lab that were not defined as potential culprit lesion by the investigators after conventional angiography. This will reflect the incidence of undiagnosed and untreated coronary culprit coronary lesion after OHCA.

  4. The percentage of stable lesions (core lab OCT) intended to be treated by PCI after peri procedural (as assessed by investigators) conventional angiography [Intra operative, up to 12 months]

    A stable lesion will be defined as a coronary stenosis ≥20% without any features of instability (no plaque rupture or erosion, no thrombosis) on core-lab OCT.

  5. The percentage of misclassification for unstable lesion between peri procedural (as assessed by investigators) OCT and core lab OCT analysis. [Intra operative, up to 12 months]

    The unstable lesion as detected during the procedure by the investigator and compared with the corelab analysis.

  6. The duration of the procedure [Intra operative, up to 12 months]

    Duration on the procedure will include timing from arterial sheath insertion to final run of angiography (angio), to final run of OCT (intracoronary imaging), and from the end of the angiography or intra coronary imaging to the end of the PCI procedure when applicable (Usually between set puncture to introducer removal).

  7. The irradiation during the procedure [Intra operative, up to 12 months]

    Patient irradiation will be determined after conventional angiography (angio), after OCT procedure (intracoronary imaging), and after PCI when applicable (angioplasty). Total procedural irradiation will also be calculated as the cumulative irradiation received during angio, intracoronary imaging and PCI if applicable.

  8. The volume of contrast dye injection [Intra operative, up to 12 months]

    The volume of contrast dye injection will be determined after conventional angiography (angio), after OCT procedure (intracoronary imaging), and after PCI when applicable (angioplasty). Total volume of contrast dye injection will also be calculated as the cumulative volume injected during angio, intracoronary imaging and PCI when applicable

  9. The rate of OCT-related complications [Intra operative, up to 12 months]

    The OCT related complications include coronary dissection, perforation, plaque embolization etc.

  10. The rate of Major Adverse Coronary and Cerebrovascular Events (MACCE). [Day 1, Day 30 and Day 90]

    The MACCE evaluation will include all-cause mortality, myocardial infarction, stroke, ischemia driven target lesion revascularization.

  11. The rate of all-cause mortality [Day 1, Day 30, Day 90 and Day 365]

    This includes all cause mortality rate

  12. The rate of stent thrombosis [Day 1, Day 30 and Day 90]

    According to Academic Research Consortium-2 (ARC2) definition

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects of age ≥ 18 years and ≤ 85 years,

  • The delay between OHCA and basic life support (no flow period) is ≤ 5 minutes,

  • First recorded ECG exhibits a shockable rhythm (ventricular tachycardia/ventricular fibrillation).

Exclusion Criteria:
  • The patient is still receiving cardiac massage at the time of admission in the cath-lab,

  • There is an obvious extra cardiac cause to the cardiac arrest (suicide, drowning, hanging, trauma etc.),

  • The patient has prior coronary artery bypass grafting,

  • The patient has incessant ventricular tachycardia/fibrillation,

  • The patient has at least one acute or chronic coronary occlusion of an epicardial coronary artery ≥2.0mm of diameter on conventional angiography, The coronary artery anatomy does not allow realization of three vessels OCT according to the interventional cardiologist (severe tortuosity, severe calcifications etc.),

  • The patient is in cardiogenic shock or with a left ventricular assistance device,

  • The post ROSC ECG (12 leads) exhibits ST segment elevation (defined as a ≥1mm ST segment elevation in two or more contiguous standard leads or as a ≥2mm ST segment elevation in two or more precordial leads),

  • The post ROSC ECG (12 leads) exhibits new left bundle block branch (LBBB).

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ Leuven Leuven Belgium 3000
2 CHU Gabriel-Montpied Clermont-Ferrand France 63000
3 CHU Timone Adultes Marseille France 13385
4 Hôpital Lariboisière Paris France 75010
5 Hôpital Cochin Paris France 75014
6 CHU Toulouse Rangueil Toulouse France 31400
7 Clinical Center of Serbia. School of medicine Belgrade Serbia 11000

Sponsors and Collaborators

  • Ceric Sàrl
  • Abbott

Investigators

  • Principal Investigator: Olivier Varenne, MD, PHD,

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ceric Sàrl
ClinicalTrials.gov Identifier:
NCT04431661
Other Study ID Numbers:
  • The CAOCT Study
First Posted:
Jun 16, 2020
Last Update Posted:
Jun 2, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2021